Asia’s first automated and intelligent in vitro organoid production system, CellXpress.ai, has been installed at Shanghai Biochip Co Ltd in Zhangjiang in the Pudong New Area, marking a major step toward the automation and standardization of organoid technology.
SBC is the national engineering center for biochip in Shanghai.
Fully automated and AI-driven, CellXpress.ai operates 24/7, delivering standardized, consistent outputs while greatly improving the growth and expansion efficiency of various stem cells, cell cultures and organoids. It enables high-throughput, industrial-scale production of high-fidelity 3D organoids, significantly reducing drug R&D costs.
The launch coincided with the establishment of the Intelligent Organoid Innovation and Industry Alliance and the Organoid and Organ-on-Chip Innovation Center, jointly initiated by SBC and Danaher Corporation. The alliance brings together medical institutions, research bodies, universities, enterprises and service providers to promote resource sharing and elevate China’s organoid innovation capacity.
Pudong, home to one of the country’s most complete biopharma ecosystems, is advancing disruptive drug discovery platforms, including high-performance molecular dynamics simulation systems. With groundbreaking systems like CellXpress.ai, Zhangjiang is accelerating the path from lab to clinic and reinforcing Shanghai’s role as a global hub for organoid technology.
